A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis)

Trial Profile

A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2016

At a glance

  • Drugs Mongersen (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IGON-1
  • Sponsors Nogra Pharma
  • Most Recent Events

    • 13 Jan 2016 Post-hoc analysis published in the Alimentary Pharmacology and Therapeutics.
    • 19 May 2015 Results (correlation of PRO2 with CDAI Score at week 12) presented at the Digestive Disease Week 2015.
    • 19 May 2015 Sub-group analysis data published in a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top